Otsuka's Sibeprenlimab Succeeds in VISIONARY IgA Nephropathy Study, Cutting Kidney-Function Event Risk 97.1%

Otsuka's sibeprenlimab succeeded in the global double-blind controlled VISIONARY study, which enrolled 510 patients with primary IgA nephropathy and showed a 97.1% reduction in the risk of kidney-function adverse events. The study also showed positive results in maintaining kidney function and improving proteinuria and hematuria, with good overall safety and tolerability over two years.